Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins manufactured from Post-COVID-19 and COVID-19-Vaccinated Plasma Donations

From September 2020, some immunoglobulin lots from US plasma contained neutralizing antibodies against the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Paralleled by the increasing numbers of post- coronavirus disease 2019 (COVID-19) donors, immunoglobulin lot antibody positivity increased to 93% by January 2021, at a mean titer of approximately 30 IU/mL. The correlation predicted that anti-SARS-CoV-2 potency would reach 345 IU/mL by July 2021. In addition to post-COVID-19 donors, the rapidly increasing number of plasma donors vaccinated against COVID-19 resulted in a mean antibody titer of >600 IU/mL in July 2021 immunoglobulin lots, with SARS-CoV-2 antibody titers for several lots even higher than those of earlier produced hyperimmune globulin products.

Automated summary

Starting from September 2020, some immunoglobulin lots from US plasma contained neutralizing antibodies against the newly emerged SARS-CoV-2. The increasing numbers of post-COVID-19 donors led to a rise in antibody positivity to 93% by January 2021, with a predicted potency reaching 345 IU/mL by July 2021. The mean antibody titer in July 2021 immunoglobulin lots, contributed by plasma donors vaccinated against COVID-19, exceeded 600 IU/mL, surpassing even the levels found in earlier hyperimmune globulin products.